Navigation Links
Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/7/2011

® in combination with Halozyme's ENHANZE™ Technology

Upcoming Anticipated Milestones

  • Reintroduce Hylenex® recombinant for the dispersion and absorption of other injected drugs and fluids in hospital and Ambulatory Surgery Centers - 4Q 2011
  • Discuss top line results from a Phase 1/2 study with HTI-501 in women with moderate to severe cellulite - 1H 2012
  • Present HannaH Phase 3 clinical trial data - 2012
  • Regulatory Submission Herceptin SC - 2012
  • Regulatory Submission Mabthera SC - 2012
  • PDUFA for Subcutaneous IgG Baxter Biosciences BLA - 2Q 2012
  • Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012

  • Third Quarter 2011 and Year-to-Date 2011 Financial ResultsThe net income for the third quarter of 2011 was $5.2 million, or $0.05 per share, compared with a net loss for the third quarter of 2010 of $(12.4) million, or $(0.13) per share. The net loss for the nine months ended September 30, 2011 was $(1.4) million, or $(0.01) per share, compared to a net loss of $(36.3) million, or $(0.39) per share, for comparable period in 2010.

  • Revenues for the third quarter of 2011 were $22.9 million, compared to $3.4 million for the third quarter of 2010. In July 2011, the Company and Baxter entered into agreements outlining certain rights, data and assets to be transferred to the Company in connection with the termination of the partnership with Baxter for the marketing rights of Hylenex recombinant. As a result, the Company recognized as revenue a one-time amount of $17.9 million from deferred revenues. Revenues in the third quarter of 2011 also consisted of a $3 million milestone payment from ViroPharma, the amortization of upfront payments received from Baxter and Roche of $0.6 million and research and development reimbursements from Baxter and Roche of $1.3 million.
  • Research and development expenses for the third quarter of 2011 were $13.5
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
    2. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
    3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
    4. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
    5. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
    6. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
    7. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
    8. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
    9. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
    (Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
    (Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
    (Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
    Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
    ... ... Presence in China, CAMBRIDGE, Mass., April 22 ... a major new research and,development center in Beijing. The initiative is ... a,long-term presence in China., The new facility will be used ...
    ... to Threat of Bioterrorism, Says UK Board ... Member General Lord Guthrie, ... to develop and deploy technology that can neutralize and destroy,a biohazardous ... has partnered with General Lord Guthrie,former chief of the British Defense ...
    ... April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,(,Lorus,), ... and,development of pharmaceutical products and technologies for ... of a development program aimed at,expanding the ... for the treatment of superficial bladder cancer., ...
    Cached Biology Technology:Genzyme to Build New R&D Center in Beijing 2Genzyme to Build New R&D Center in Beijing 3Genzyme to Build New R&D Center in Beijing 4Genzyme to Build New R&D Center in Beijing 5Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 2Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 3Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4
    (Date:7/10/2014)... of enzymes known as heme enzymes, due to the ... At the centre of the heme cofactor is an ... reacting heme is in an intermediate state called Compound ... is whether this oxidation involves just an oxygen atom ... question has implications for understanding oxidative processes within living ...
    (Date:7/10/2014)... (ACS) announced today that Courtney Aldrich, Ph.D., will ... Diseases as editor-in-chief. With the first issue ... journal will meet a growing demand for a ... , "Our vision is to develop a journal ... the basic science that advances the field and ...
    (Date:7/10/2014)... from The University of Texas Health Science Center at ... (IYG), a health education program designed to delay sexual ... dating violence behaviors among minority youth. , According to ... of high school youth are victims of physical dating ... percent are victims of emotional dating violence. Previous studies ...
    Breaking Biology News(10 mins):Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2
    ... NEW YORK, February 4, 2011 A defining feature ... today,s age of computational science, this means higher standards ... that generated the results along with the published research ... widely accessible, facilitating re-use and verification of results. ...
    ... the annual meeting of the American Association for the Advancement ... climate change could increase exposure and risk of human illness ... studies projecting impacts to be felt within 30 years. ... warmest for sea surface temperatures, NOAA and our partners are ...
    ... Among the many differences between girls and boys, add the ... the list. , Results of a double-blind, placebo-controlled, dose-response study ... general, boys get a greater rush and more energy from ... caffeine had a positive effect on their athletic performance. Girls ...
    Cached Biology News:AAAS Symposium: New research facilitates scientific knowledge transfer 2Climate projections show human health impacts possible within 30 years 2Climate projections show human health impacts possible within 30 years 3Climate projections show human health impacts possible within 30 years 4High-caffeine-consuming boys get greater rush from caffeine than girls 2High-caffeine-consuming boys get greater rush from caffeine than girls 3
    ...
    Jak3 Antibody Ship: Hot Store: -20 C...
    WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Applications: Western blotting Stability: Room temperature, indefinitely ...
    Biology Products: